In summary, N2 represents a potent differentiation therapy candidate for erythroleukemia, uniquely targeting JAK2 and activating downstream JAK2/STAT3, JAK2/PKCδ/STAT3 and JAK2/PKCδ/MAPK pathways to facilitate megakaryocytic differentiation (Figure 17). This evidence concerns the gene STAT3 and erythroleukemia.